Recently, pharmacology, toxicity and human research were published in multiple peer-reviewed journals. GlucoMedix was compared to Glibenclamide, Enalapril and Atorvastatin producing similar pharmacological effects. Acute and subacute oral toxicity was performed with no toxicity, abnormal clinical chemistry or haematological effects observed. In a six patient case series, GlucoMedix reduced glucose levels and the need for pharmaceuticals in patients with type 2 diabetes. Although multiple prescription drugs are well known for the treatment of individual comorbidities of metabolic syndrome, no drug monotherapy concurrently treats all three comorbidities.